Jaguar Health Soars 11.06% on Crofelemer Study Hopes

On April 29, 2025, Jaguar Health's stock surged by 11.06% in pre-market trading, reflecting significant investor interest and optimism surrounding the company's recent developments.

Jaguar Health is set to present initial results from a proof-of-concept study of crofelemer, its plant-based anti-secretory prescription drug, in patients with microvillus inclusion disease (MVID) and short bowel syndrome with intestinal failure (SBS-IF). The webcast, scheduled for April 30, 2025, will review the patient experience, the impact of crofelemer on disease progression, and quality of life improvements for MVID and SBS-IF patients.

The study, conducted at Sheikh Khalifa Medical City in Abu Dhabi, is led by Dr. Mohamad Miqdady, a recognized leader in pediatric gastroenterology. The webcast will feature commentary from key opinion leaders, including Dr. Miqdady and Dr. Christos Tzivinikos, providing insights into the trial's findings and the potential of crofelemer in treating these rare diseases.

Jaguar Health is currently supporting multiple proof-of-concept investigator-initiated trials and conducting placebo-controlled Phase 2 studies for crofelemer in various regions, including the United States, European Union, and Middle East/North Africa. The company's ongoing efforts to evaluate the efficacy of crofelemer for MVID and SBS-IF patients are expected to provide additional preliminary data on the drug's safety and potential effectiveness throughout 2025.